¿ Aclara BioSciences Inc., of Mountain View, Calif., and Cepheid, of Sunnyvale, Calif., said they have been awarded a $3 million grant from the Defense Advanced Research Projects Agency. The companies will codevelop an integrated microfluidic system designed to perform automated measurements to simultaneously detect biological agents or genetically engineered variants.
¿ Affymetrix Inc., of Santa Clara, Calif., said it entered into an EasyAccess Silver agreement with the Procter & Gamble Co., of Cincinnati, giving P&G broad access to standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in its research and development activities. P&G affiliates also have the option to access the technology on the same terms.
¿ Agritope Inc., of Portland, Ore., said it was awarded a Phase I grant from the U.S. Department of Agriculture under its Small Business Innovation Research Program. The grant will provide $70,000 over six months to fund research involving the use of synthetic compounds to improve plant production.
¿ Alliance Pharmaceutical Corp., of San Diego, said enrollment has been completed in a pivotal Phase III study with Oxygent. The trial enrolled 484 patients undergoing orthopedic, cancer, urologic, vascular and other high blood loss, general surgery procedures. Preliminary results are expected this fall.
¿ Atrix Laboratories, of Fort Collins, Colo., said it completed the enrollment of patients in its Phase III trial for advanced prostate cancer. The therapy uses the company's Atrigel drug delivery system to administer a 30-day sustained release of leuprolide acetate subcutaneously. A total of 120 patients are enrolled, and the trial is expected to be completed by the end of the year. The company plans to submit a new drug application in 2001.
¿ Biocore , of Uppsala, Sweden, will set up a new pharmaceutical and biotechnology business unit, in Neuchatel, Switzerland. The unit will manage both the company's operational activities and further develop business relationships with the pharmaceutical and biotechnology industries.
¿ Celsion Corp., of Columbia, Md., said it has begun trading on the American Stock Exchange under the symbol CLN.
¿ CRS Robotics Corp., of Burlington, Ontario, entered into a supply agreement with St. Louis-based Monsanto Co. The order, which is in excess of $1.2 million, covers the first two automated lab systems designed to help Monsanto conduct high-throughput genotyping at the Monsanto facility in Ankeny, Iowa. Two additional systems are planned for the fourth quarter. In addition, CRS sold a new automated laboratory system to the National Research Council in Canada. The CRS system for the council's Plant Biotechnology Institute will combine DNA purification and DNA amplification to determine the DNA sequence of a large number of expressed genes from canola and wheat. The company also completed the installation of two DNA Purification systems for the Department of Energy's Joint Genome Institute production sequencing facility in Walnut Creek, Calif.
¿ Cubist Pharmaceuticals Inc., of Cambridge, Mass., said it expects to begin a Phase III pneumonia trial testing Cidecin (daptomycin for injection) by the end of 2000. The company also presented positive data on Cidecin from its Phase II bacteremia trial at the 10th European Congress of Microbiology and Infectious Diseases in Stockholm, Sweden. Combined data of two Phase II studies including 101 patients showed daptomycin had an overall clinical success rate of 92 percent in the modified intent-to-treat population and 100 percent in the clinically evaluable patients. It demonstrated a 75 percent success rate in terms of microbiologic eradication in modified intent-to-treat patients and a 93 percent success rate in microbiologically evaluable patients. Daptomycin is in multiple Phase III trials to treat complicated skin and soft tissue infections.
¿ Entropin Inc., of Indio, Calif., said it sold an additional 180,000 shares of common stock and 300,000 stock purchase warrants upon exercise of the underwriter overallotment option in its secondary public offering. The company sold 2 million shares and 2 million purchase warrants generating proceeds of $14.5 million in the secondary offering that closed March 20. The 2.3 million stock purchase warrants, if fully exercised, have the potential of producing an additional $24 million for the company. The offering was underwritten by Neidiger, Tucker, Bruner Inc. and Westport Resources Investment Services Inc.
¿ Genelabs Technologies Inc., of Redwood City, Calif., said it began submission of a new drug application for GL701 to treat chronic autoimmune disease systemic lupus erythematosus. The submission includes the clinical, statistical and human pharmacokinetic sections of the NDA. The company expects to complete its submission by the end of 2000. (See BioWorld Today, Nov. 23, 1999, p. 3.)
¿ Hemispherx Biopharma Inc., of Philadelphia, said its licensing partner, Bioclones Ltd., of South Africa, initiated Ampligen treatment of severe chronic fatigue syndrome on a named-patient, cost-recovery basis in Great Britain.
¿ IGT Pharma Inc., of Vancouver, British Columbia, said results from an animal study show that IGT440103 provided significant protection to living brain cells subjected to the conditions of stroke. The compound was up to 30 times more potent in achieving equivalent therapeutic results when compared to the accepted research standard, the company said.
¿ Immtech International Inc., of Vernon Hills, Ill., said manufacturing has been completed for the Phase I trial of DB-289 in Pneumocystis carinii pneumonia, scheduled to begin in the third quarter. MediChem Research Inc., of Lemont, Ill., produced the drug.
¿ InKine Pharmaceutical Co. Inc., of Blue Bell, Pa., said it completed a study comparing the bioavailability of a commercially viable tablet formulation of CBP-1011 to the capsule formulation that is being used in the company's Phase III studies in patients with idiopathic thrombocytopenic purpura. The study enrolled 24 healthy volunteers, each of whom received a single dose of each formulation, separated by 21 days. Preliminary results indicate that the bioavailability of the tablet formulation does not differ significantly from that of the capsule formulation.
¿ Lexicon Genetics Inc., of The Woodlands, Texas, said it is using its knockout mouse technology to create a model for Canavan disease. The mice were developed through a research collaboration between Lexicon and scientists at University of Texas Medical Branch at Galveston. Details of the model system are published in the current issue of The Journal of Gene Medicine.
¿ LifeSpan BioSciences Inc., of Seattle, said it entered into an agreement with Novartis Research Foundation for a subscription to the first database of information on the expression and localization of G protein-coupled receptors (GPCR). The database will provide information for the identification and validation of new target genes for drug discovery efforts. In March, LifeSpan signed Pfizer Inc., of New York, as its first subscriber to GPCRs in human tissue. (See BioWorld Today, March 8, 2000, p. 1.)
¿ Myriad Genetics Inc., of Salt Lake City, said it has identified two novel proteins that currently are being evaluated by Pharmacia Corp.'s G.D. Searle & Co. unit through its collaboration with Myriad. The proteins were identified through the use of Myriad's high-throughput automated ProNet technology. Myriad formed a collaboration with Pharmacia, formerly Monsanto Co., of St. Louis, in November 1998. (See BioWorld Today, Nov. 13, 1998, p. 1.)
¿ Oncolytics Biotech Inc., of Calgary, Alberta, said it received approval to have its shares listed on the Toronto Stock Exchange under the symbol ONC.
¿ Orchid BioSciences Inc., of Princeton, N.J., and Luminex Corp., of Austin, Texas, said they entered into a collaboration to develop an affordable, rapid-throughput system for conducting single nucleotide polymorphism scoring. The new system, based on Luminex's open-platform LabMAP system, will be commercialized by Orchid as part of its growing line of SNPstream instruments and SNPware consumables. Orchid will market the new SNPstream product line.
¿ Paradigm Genetics Inc., of Research Triangle Park, N.C., said the underwriters of its recent initial public offering have exercised their overallotment option and purchased an additional 750,000 shares at $7 per share. A total of 6.75 million shares of common stock were offered and sold in the offering, bringing the total gross proceeds to $47.25 million. The offering was made by an underwriter group led by New York-based Chase H&Q, and included J.P. Morgan, of New York; Pacific Growth Equities, of San Francisco; and Stephens Inc.
¿ Progen Industries Ltd., of Brisbane, Australia, said its compound PI-88 will move into Phase II cardiovascular trials. The trials will test the product in preventing blood clots in thromboembolic diseases and angioplasty-induced restenosis. The company expects to begin the trials in 2001.
¿ Repair Inc., of Boston, said it raised $2 million in seed financing to develop therapies for cardiovascular diseases based on its proprietary drug delivery and angiogenesis technologies. The funds will support the development and entry into clinical trials of the company's first product, a sustained-delivery formulation of fibroblast growth factor to treat coronary artery disease. Institutional founders and investors of Repair include Maine Medical Center and Masthead Venture Partners.
¿ The Michigan Economics Development Corp., of Lansing, Mich., has received more than 500 proposals from high-tech and biotechnology companies wanting some of the $50 million the state has allocated to create new life sciences firms. The companies requested a total of more than $600 million in funding, the state said. Michigan wants to use part of its tobacco settlement money to establish a Life Science Center. Michigan offered a $50 million incentive to fund organizations willing to locate their business to the state as part of its $1 billion plan to establish itself as a major research hub. Grant funding is available in three categories: general research, applied research and commercialization/product development activities.
¿ ViroPharma Inc., of Exton, Pa., filed a registration statement registering the resale of its 6 percent subordinated convertible notes due March 1, 2007, by certain holders of the notes.